NRG
VRTX icon

Nemes Rush Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Nemes Rush Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.77M Sell
5,579
-26
-0.5% -$11.5K 0.23% 71
2026
Q1 		$2.5M Sell
5,605
-132
-2% -$61.6K 0.24% 68
2025
Q4 		$2.6M Sell
5,737
-13
-0.2% -$5.6K 0.24% 66
2025
Q3 		$2.25M Buy
5,750
+27
+0.5% +$11.3K 0.22% 71
2025
Q2 		$2.55M Buy
5,723
+977
+21% +$450K 0.28% 65
2025
Q1 		$2.3M Sell
4,746
-112
-2% -$52.2K 0.29% 59
2024
Q4 		$1.96M Buy
4,858
+142
+3% +$65.8K 0.24% 65
2024
Q3 		$1.97M Sell
4,716
-9
-0.2% -$4.32K 0.29% 65
2024
Q2 		$2.21M Buy
4,725
+9
+0.2% +$3.91K 0.3% 58
2024
Q1 		$1.97M Sell
4,716
-18
-0.4% -$7.61K 0.28% 65
2023
Q4 		$1.93M Sell
4,734
-32
-0.7% -$11.8K 0.31% 62
2023
Q3 		$1.66M Sell
4,766
-18
-0.4% -$6.29K 0.3% 67
2023
Q2 		$1.68M Buy
+4,784
New +$1.61M 0.3% 69

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nemes Rush Group's VRTX Position: Q2 2026 in Review

Nemes Rush Group reduced its Vertex Pharmaceuticals (VRTX) stake by 0.46% in Q2 2026, selling an estimated $11.5K and leaving 5,579 shares worth $2.77M. The position accounts for 0.23% of the portfolio, ranked #71.

Nemes Rush Group first reported a position in VRTX in Q2 2023 and has held it in 13 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Nemes Rush Group held 5,579 shares of Vertex Pharmaceuticals worth $2.77M as of Q2 2026.
  • Nemes Rush Group sold 26 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
  • Vertex Pharmaceuticals made up 0.23% of Nemes Rush Group's portfolio in Q2 2026, its #71 holding.
  • Nemes Rush Group first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.